BioDiem partner close to filing for vaccine exports
12 December, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) partner Serum Institute of India will file for WHO approval in early 2013 to export flu vaccines based on BioDiem's LAIV platform.
Patrys (ASX:PAB) hits myeloma trial milestone
10 December, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed the main round of dosing for the first three patients enrolled in a German trial of its PAT-SM6 antibody in multiple myeloma.
Cavatak shows potential against bladder cancer
29 November, 2012 by Dylan Bushell-EmblingEarly research into Viralytics' (ASX:VLA) Cavatak oncolytic virus shows it effectively targets receptors on bladder cancer tissue.
Getting to the heart of Prader-Willi Syndrome
19 November, 2012 by Tim DeanResearchers at the Garvan Institute have found a sign that the rare genetic disorder, Prader-Willi Syndrome, is linked to problems in the autonomic nervous system.
Comment: Medical research key to improving the health and wealth of Australia
16 November, 2012 by Staff WritersProfessor Brendan Crabb, incoming President of AAMRI, outlines the priorities he sees for health and medical research in Australia at a time of budget cuts and systemic challenges.
Sir Gus Nossal and Ita Buttrose receive gongs at Research Australia Awards
15 November, 2012 by Staff WritersAustralia’s leading health and medical researchers and advocates have been recognised in the Research Australia Awards.
Garvan team solve autoimmune mystery
09 November, 2012 by Tim DeanA team at the Garvan Institute has solved a longstanding mystery as to how some autoimmune diseases can be triggered by wayward B cells.
Predicting cancer: it’s all in the numbers
07 November, 2012 by Tim DeanAustralian researchers have developed a statistical model that will help identify people with a high risk of bowel and endometrial cancer.
Next generation sequencing reveals pancreatic cancer’s secrets
29 October, 2012 by Tim DeanA new genomic study shows pancreatic cancer is not just a single cancer but has many variations, requiring potentially many different treatments.
Slideshow: BrainArt
15 October, 2012 by Staff WritersThe BrainArt Exhibition integrates the artistic and scientific worlds, depicting the application of neuroscience in our daily lives.
Co-opting a killer virus peptide to combat cancer
08 October, 2012 by Tim DeanA team at RMIT has used an advanced new technique to synthesise a key peptide from the myxoma virus that is responsible for its cancer killing clout, and have found this peptide can do its dirty work without harming healthy cells
AHG’s CardioCel receives special access approval from TGA
26 September, 2012 by Dylan Bushell-EmblingAllied Healthcare has had a win in the step to see its congenital heart defect treatment, CardioCel, approved for use across Australia.
Chris Goodnow receives GSK Award for pioneering autoimmune research
12 September, 2012 by Tim DeanProfessor Chris Goodnow has received the $80,000 GlaxoSmithKline Award for Research Excellence which will fund his research into a controversial theory on the origin of autoimmune diseases.
Science in the blood: L’Oreal Fellowship awarded to WEHI’s Kylie Mason
21 August, 2012 by Tim DeanOne of the three L’Oreal Fellowships has been awarded to Dr Kylie Mason for her work understanding the relationship between cancer and blood.
Epigenetics discovery aids prostate cancer diagnosis
07 August, 2012 by Tim DeanThe discovery of a microRNA that appears to affect prostate cancer proliferation and metastasis could prove a valuable biomarker for diagnosis.
